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Introduction {#ijc32138-sec-0001}
============

Lipid metabolism is highly relevant in cancer, as supported by numerous studies describing a role for lipids in cancer‐related cellular processes, such as proliferation and invasion.[1](#ijc32138-bib-0001){ref-type="ref"}, [2](#ijc32138-bib-0002){ref-type="ref"} The increased ability of cancer cells to synthesize lipids has led to the assumption that lipogenesis is the main mechanism by which cancer cells acquire fatty acids. Indeed, elevated expression and activity of enzymes involved in lipogenesis, such as fatty acid synthetase (FASN) are observed in tumour cells and correlate with cancer progression and worse prognosis in breast cancer patients.[3](#ijc32138-bib-0003){ref-type="ref"} However, a recent study uncovered a pathway of fatty acid supply to cancer cells *via* lipoprotein lipase (LPL)‐mediated lipolysis of extracellular lipoproteins.[4](#ijc32138-bib-0004){ref-type="ref"} This showed that not all cancer cells rely exclusively on *de novo* fatty acid synthesis (FAS), but can also be fuelled by exogenous lipids. What determines the relative contribution of the lipogenic *vs*. the lipolytic pathways to the intracellular lipid pool is currently unknown.[2](#ijc32138-bib-0002){ref-type="ref"} Both pathways may be coupled to meet the increased demands of highly proliferating cancer cells for fatty acids as building blocks for more complex lipids. Alternatively, the metabolic fates of fatty acids derived from exogenous and endogenous sources may be different. The present study provides evidence that oxidative stress is a key factor shifting the balance towards increased activity of the lipolytic pathway by upregulating Lipase G, endothelial type (LIPG).

LIPG was originally identified in endothelial cells[5](#ijc32138-bib-0005){ref-type="ref"} as a further member of the triglyceride lipase family[6](#ijc32138-bib-0006){ref-type="ref"} and is a cell surface‐associated lipase with predominantly phospholipase A1 activity. It cleaves phosphatidylcholine (PC) from high‐density lipoproteins (HDL), thereby releasing free fatty acids (FFAs) and lysophosphatidylcholine (LPC), which can be taken up by cells.[7](#ijc32138-bib-0007){ref-type="ref"} Due to its impact on HDL metabolism, LIPG has over past decades been primarily studied in the context of cardiovascular disease. Studies on a role for LIPG in cancer are scarce. We previously reported the upregulation of *LIPG* mRNA in a model of oncogene‐induced senescence (OIS) in MCF‐7 breast cancer cells, as part of the gene expression alterations that accompany senescence‐associated remodelling of phospholipids.[8](#ijc32138-bib-0008){ref-type="ref"} Later, Slebe and coworkers[9](#ijc32138-bib-0009){ref-type="ref"} reported a broad and molecular subtype‐independent expression of LIPG in breast cancer and a role for LIPG in providing lipids for tumour growth. Recently, Lo and coworkers[10](#ijc32138-bib-0010){ref-type="ref"} described expression of LIPG in triple‐negative breast cancer and a role for LIPG (independent of its catalytic activity) in promoting metastasis and invasiveness. While the discrepancy in the expression pattern of LIPG in breast cancer still needs to be clarified, these reports suggest a multifaceted role of LIPG in tumour progression that deserves further studies. Remarkably, despite the essential functions of LIPG discovered in experimental models no significant association of LIPG with survival has been observed in human breast cancer.[9](#ijc32138-bib-0009){ref-type="ref"}

Our initial finding that LIPG is upregulated in oncogene‐induced senescence -- a state of hypermitotic arrest ‐ prompted us to hypothesize that LIPG is necessary for survival under stress conditions, most probably due to its ability to supply cells with free fatty acids. Here, we report a new and proliferation‐independent role for LIPG in oxidative stress‐triggered lipid droplet accumulation that confers resistance to reactive oxygen species. Furthermore, in a systematic analysis of own and publicly available Affymetrix gene expression data we show that high *LIPG* mRNA expression is restricted to a small subset of breast tumours that are predominantly high grade and oestrogen receptor (ER)‐negative. Finally, we demonstrate that high *LIPG* mRNA expression is significantly associated with shorter metastasis‐free survival (MFS) in node‐negative breast cancer.

Material and Methods {#ijc32138-sec-0002}
====================

Chemicals {#ijc32138-sec-0003}
---------

5‐Tetradecyl‐oxy‐2‐furoic acid (TOFA), cerulenin, CoCl~2~, N‐acetyl‐cysteine (NAC) and lapatinib, were obtained from Sigma Aldrich. GSK264220A, rotenone, and glutathione (GSH, reduced ethyl ester) were purchased from Cayman Chemical. The ROS scavenger MnTMPyP was purchased from Calbiochem/Merck and diphenyleleiodonium (DPI) from Enzo Biochem.

Cell culture and treatments {#ijc32138-sec-0004}
---------------------------

The MCF‐7 and the SKBR3 breast carcinoma cell lines were obtained from the American Type Culture Collection (ATCC, LGC Standards GmbH). MDA‐MB‐231, MDA‐MB‐468 and HCC1954 cells were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ). BT747 and T47D cells were obtained from Cell Lines Service (CLS). The MCF‐7/NeuT cell line was generated and cultivated as described elsewhere.[8](#ijc32138-bib-0008){ref-type="ref"}, [11](#ijc32138-bib-0011){ref-type="ref"}, [12](#ijc32138-bib-0012){ref-type="ref"} These cell lines were cultured at 37 °C in a humidified 5% CO~2~ air atmosphere. MCF‐7, MCF‐7/NeuT, MDA‐MB‐231, MDA‐MB‐468 and SK‐BR‐3 cells were maintained in Dulbecco\'s modified medium (DMEM, 4.5 g/l glucose, PAN‐Biotech), supplemented with 10% foetal bovine serum (FBS, PAN‐Biotech). For the MCF‐7/NeuT cell line tetracyclin‐free FBS (PAN‐Biotech) was used. BT‐474 and T‐47D cells were maintained in DMEM:F12, 10% FCS and 1% L‐Glutamine (all from PAN‐Biotech) and HCC1954 cells were cultivated in RPMI1640 with 10% FCS and 1% Sodium Pyruvate (Gibco). The HER2 wildtype and HER2 insYVMA MCF7 cell lines were established by retroviral transduction of MCF‐7 cells with the corresponding plasmids[13](#ijc32138-bib-0013){ref-type="ref"} and cultivated in RPMI with 10% FCS, 1% Pen/Strep and 1% L‐Glutamine in the presence of puromycin (0.250 μg/mL). Cell exposure to hypoxia (1% O~2~) was performed in a modular hypoxia/hyperoxia CO~2~ incubator (CB53, Binder). The cell culture media was pre‐equilibrated in the hypoxia incubator over night. Expression of LIPG and ACACA (the gene coding for the catalytic subunit alpha of Acetyl‐CoA Carboxylase) was transiently downregulated using siRNA as described in Supplemental Material.

All cell lines were regularly tested for mycoplasma (Venor GeM Classic Mycoplasma Detection kit, Minerva Biolabs), and authenticated (DSMZ).

LIPG overexpression {#ijc32138-sec-0005}
-------------------

MCF7 cells were transiently transfected with the full‐length human LIPG cDNA cloned into pCMV/hygro--FLAG vector or with the empty vector (Sino Biological Inc.). Transfections were performed with the X‐tremeGENE HP DNA transfection reagent according to the manufacturer\'s instructions (Sigma Aldrich) for 48 h. When applicable, 48 h after transfection cells were fed with either 800 μg high density lipoprotein (HDL, BioTrend) or 800 μg phospholipid (1,2‐dioleoyl‐sn‐glycero‐3‐phosphocholine DOPC (PC‐OA) (Avanti Polar Lipids) for a further 48 h. HDL was purchased 'ready to use'. Preparation of phospholipid vesicles and oleic acid/bovine serum albumin (OA/BSA) complex is described in Supplemental Material.

Immunoblotting {#ijc32138-sec-0006}
--------------

Standard immunoblot analysis was performed as described elsewhere.[11](#ijc32138-bib-0011){ref-type="ref"} Antibodies were diluted in 5% BSA/Tris‐buffered saline Tween‐20. Details about source, dilution and incubation conditions are provided in Supplemental Material. Protein signals were detected by enhanced chemiluminiscence (PerkinElmer LAS). Quantification of Western blots was done with ImageJ. The density of the protein of interest was always adjusted to the density of the corresponding loading control.

Triacylglyceride quantification {#ijc32138-sec-0007}
-------------------------------

Triglyceride levels in cells were quantified using the commercially available Triglyceride Quantification Kit (Abcam), according to the manufacturer\'s instructions. The fluorescence (Ex/Em 535/587 nm) was measured using a Tecan Infinite 200PRO plate reader (Tecan Group AG). The protein concentration of the extract was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), according to the manufacturer\'s instructions, and used to normalize the fluorescent signal.

Quantification of mitochondrial membrane potential {#ijc32138-sec-0008}
--------------------------------------------------

Cells were incubated with tetramethylrhodamine methylester perchlorate (TMRE) (Invitrogen), for 20 min at 37 °C at a final concentration of 10 μM in medium containing serum. After washing with PBS, cells were trypsinized and the fluorescence of loaded TMRE (Ex/Em 545/575) was quantified in a plate reader (Tecan SpectraFluor Plus). For normalization, cell number was determined with a CASY cell counter (Innovatis AG/Roche).

Quantification of reactive oxygen species with the TBARS assay {#ijc32138-sec-0009}
--------------------------------------------------------------

Quantification of malondialdehyde (MDA) in cells (2x10^7^ cells collected in 1 mL PBS) was performed with the TBARS assay (Cayman Chemical) according to the colorimeric version of the manufacturer\'s instructions. Absorbance was read at 530--540 nm with a plate reader (Tecan SpectraFluor Plus).

Viability assay {#ijc32138-sec-0010}
---------------

Determination of the number of viable cells after treatments in multiwell plates was performed with the CellTiter‐Blue® Cell Viability Assay (Promega) according to manufacturer\'s instructions. MCF‐7 cells were incubated with the redox dye resazurin for 4 h. The fluorescent end product was measured in a Greiner 96 Flat Bottom Black Polystyrol 96‐well plate (Ex/Em 540/590 nm) using a Tecan Infinite 200PRO plate reader (Tecan Group AG).

Immunofluorescence analysis {#ijc32138-sec-0011}
---------------------------

Cells were seeded on coverslips and, after the indicated treatments, a standard immunofluorescence protocol was performed. Details about source, dilution of the antibodies used and incubation conditions are provided in Supplemental Material. Coverslips were mounted and examined under a confocal laser scanning microscope (Olympus CLSM FV1000).

For visualization of lipid droplets, cells were stained after fixation and permeabilisation with either Oil Red O (Sigma Aldrich) for 30 min[14](#ijc32138-bib-0014){ref-type="ref"} or with BODIPY® 493/503 (Life technologies) for 45 min. For visualization of actin filaments, cells were stained with rhodamine‐labeled phalloidin (Invitrogen) for 45 min at room temperature.

Quantitative PCR {#ijc32138-sec-0012}
----------------

Total RNA extraction was performed with either the RNeasy Mini Kit (Qiagen) or the innuPREP RNA kit (Analytic Jena), according to the standard protocol of the manufacturer. RNA (2 μg) was transcribed to cDNA using the High‐Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real‐time quantitative PCR was performed with the Applied Biosystems ABI 7500 Fast Real‐Time PCR System using the TaqMan technique. UBC was used as the reference gene for normalization. Taqman expression assays are found under Supplemental Material. Relative gene expression was calculated according to the 2‐ΔΔCt method.[15](#ijc32138-bib-0015){ref-type="ref"}

Heparin‐release {#ijc32138-sec-0013}
---------------

For detection of the secreted, cell surface‐bound fraction of LIPG, cells were washed with PBS and incubated in serum‐free medium containing 10--25 U/mL heparin (Sigma Aldrich) for 16 h at 37 °C. The cell supernatants were collected in ice‐cold tubes and after removal of dead cells by centrifugation, protein was precipitated using a standard ammonium sulfate precipitation procedure. Protein pellets were analysed by immunoblotting. Because no loading control was available for the immunoblotting of the supernatants, the signal intensity calculated with ImageJ was normalized to the total amount of protein of the corresponding cell cultures.

Immunohistochemistry of breast cancer tissue {#ijc32138-sec-0014}
--------------------------------------------

Formalin‐fixed paraffin‐embedded (FFPE) tissue blocks from 258 node‐negative, systemically untreated, breast cancer patients (See Table [S1](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information with clinicopathological characteristics), who were operated between 1988 and 2000 at the Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, were used to construct a tissue microarray (TMA). The study was approved by the Research Ethics Committee of the University Medical Centre Mainz, Germany, and informed consent was obtained from all patients. Description of TMA construction and staining procedure is found in Supplemental Material. The stained TMA slides were scanned using a Hamamatsu NanoZoomer 2.0 whole slide scanner. LIPG cytoplasmic positivity was assessed by manual annotation of the scanned images at 10‐40x magnification, based on the staining intensity which was categorized as (0) negative/weak, (1) moderate, and (2) strong. One score was obtained from the duplicate tissue cores representing each tumour.

Transcriptomics datasets {#ijc32138-sec-0015}
------------------------

LIPG (probeset 219181_at), PLIN2 (209122_at) and TXNRD1 (201266_at) expression in human breast cancer were analysed in Affymetrix GeneChip HG U133 A or Plus 2.0 gene expression microarray datasets that were accessed from the Gene Expression Omnibus (GEO) web portal (<https://www.ncbi.nlm.nih.gov/geo/>).[16](#ijc32138-bib-0016){ref-type="ref"} Duplicated patients were excluded. Clinicopathological characteristics and literature references for the analysed cohorts are summarized in Table [S2](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information. Frozen robust multiarray analysis (fRMA)[17](#ijc32138-bib-0017){ref-type="ref"} was used for the normalization of the Affymetrix data.

For additional analysis of LIPG expression, RNA‐seq data from the Cancer Genome Atlas (TCGA) breast cancer dataset (BRCA) was used, including 1,125 tumour and 97 matched healthy tissue samples, accessed from the Genomic Data Commons (GDC) web portal (<https://gdc-portal.nci.nih.gov>/), as described.[18](#ijc32138-bib-0018){ref-type="ref"} The TCGA BRCA dataset included 180 stage I, 609 stage II, 243 stage III, and 20 stage IV tumours (for 11 tumours, no information about stage was available).

Statistical analysis {#ijc32138-sec-0016}
--------------------

All analyses of transcriptomics data were performed using R version 3.2.1 (R core team, 2015, <http://www.r-project.org>/). Categorization of clinical variables age, grade, pT stage, ER and HER2 status, dichotomization of LIPG expression, calculation of univariate and multivariate Cox analysis and likelihood ratio statistic are described in detail in Supplementary Material. Analyses of cell culture results were performed using GraphPad Prism, version 6 (La Jolla, CA, USA).

Results {#ijc32138-sec-0017}
=======

LIPG enables cancer cells to use circulating lipoproteins as a nutrient source and promotes lipid storage {#ijc32138-sec-0018}
---------------------------------------------------------------------------------------------------------

Previous work has shown that LIPG exerts phospholipase A1 activity towards high‐density lipoprotein (HDL)‐derived phosphatidylcholine (PC),[19](#ijc32138-bib-0019){ref-type="ref"} releasing lipid products that become incorporated into intracellular PC and triacylglyceride (TAG) pools.[7](#ijc32138-bib-0007){ref-type="ref"} Therefore, we investigated whether this also applies to breast cancer cells. First, endogenous expression of *LIPG* mRNA was measured in breast cancer cell lines of different subtypes: MCF‐7 and T47D (ER+/HER2‐), BT474 (ER+/HER2+), MDA‐MB231 and MDA‐MB‐468 (ER‐/HER2‐) and SKBR3 and HCC1954 (ER‐/HER2+). The results revealed the lowest *LIPG* mRNA levels in MCF‐7 and the highest in MDA‐MB‐468 and HCC1954 cells (Fig. [S1](#ijc32138-supitem-0001){ref-type="supplementary-material"}a, Supporting Information). This expression pattern was supported by Western blot analysis of the cell culture supernatants, but was not observed in cell lysates (Fig. [S1](#ijc32138-supitem-0001){ref-type="supplementary-material"}b, Supporting Information), indicating that LIPG transcription is followed by secretion of the mature 68 kDa LIPG protein.

LIPG was overexpressed in MCF‐7 cells using a vector containing *LIPG* tagged at the C‐terminus with a FLAG epitope and overexpression was confirmed by qPCR, immunoblotting and immunofluorescence (Figs. S2a‐S2c, Supporting Information). LIPG overexpression (LIPG‐OE) in the presence of HDL resulted in an increase in intracellular TAG levels, as well as in the upregulation of the lipid droplet (LD)‐coating protein Perilipin 2 (*PLIN2*), and LD accumulation (Fig. [1](#ijc32138-fig-0001){ref-type="fig"} *a*) compared to cells transfected with vector alone (EV) and to non‐transfected cells (FM control, Fig. S2d, Supporting Information). Besides HDL, also pure PC vesicles (PC esterified with oleic acid (PC‐OA) served as a LIPG substrate, resulting in elevated levels of TAG, increased accumulation of LD, and upregulation of *PLIN2* expression (Fig. [1](#ijc32138-fig-0001){ref-type="fig"} *b*). Addition of OA, one of the most abundant fatty acids released by LIPG,[20](#ijc32138-bib-0020){ref-type="ref"} to both LIPG‐OE and EV‐transfected cells resulted in comparable increases in TAG accumulation, *PLIN2* upregulation and LD accumulation irrespective of LIPG expression (Fig.[1](#ijc32138-fig-0001){ref-type="fig"} *c*) as also shown in OA‐treated parental MCF‐7 cells (Fig. S2e, Supporting Information). LIPG overexpression in absence of substrate (Fig. [1](#ijc32138-fig-0001){ref-type="fig"} *d*) did not elicit such a response, suggesting that both LIPG and substrate are required to increase the intracellular TAG pool. These results demonstrate that MCF‐7 breast cancer cells are able to incorporate exogenous free fatty acids into TAGs, but only LIPG expression renders them capable of using HDL or PC as a fatty acid source.

![LIPG overexpression in MCF‐7 cells results in intracellular lipid storage. MCF‐7 cells were transfected with a LIPG construct (LIPG‐OE) or an empty vector (EV) and incubated for 48 h with (*a*) 800 μg HDL, (*b*) 800 μg PC‐OA in serum‐free DMEM, (*c*) 800 μg oleic acid (OA) complexed to bovine serum albumin and (*d*) no substrate. Intracellular triacylglyceride (TAG) levels were quantified with the triglyceride quantification assay kit. *PLIN2* mRNA levels were analysed by qPCR. Lipid droplets were visualized with Bodipy 493/503 staining (green). Nuclei were stained with DAPI (blue). The bars represent the mean ±SEM and pictures are representative of three independent experiments. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001, unpaired two‐tailed Student\'s t‐test. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-901-g001){#ijc32138-fig-0001}

Given that LIPG overexpression results in intracellular lipid storage in MCF‐7 cells, we investigated whether upregulation of endogenous LIPG by sustained oncogenic signalling in MCF‐7/NeuT cells was also associated with elevated intracellular TAG. Previously, we observed upregulation of *LIPG* mRNA in MCF‐7/NeuT breast cancer cells which conditionally overexpress an oncogenic variant of the rat Her2/Erbb2/Neu receptor tyrosine kinase (NeuT), leading to oncogene‐induced senescence (OIS).[8](#ijc32138-bib-0008){ref-type="ref"} After demonstrating doxycycline (dox)‐triggered expression of NeuT, together with the EGFP reporter and the characteristic morphological changes associated with premature senescence, such as cell enlargement and flattening (Figs. [2](#ijc32138-fig-0002){ref-type="fig"} *a* and 2*b*), we confirmed a more than tenfold upregulation of *LIPG* mRNA by qPCR (Fig. [2](#ijc32138-fig-0002){ref-type="fig"} *c* and Fig. S3a, Supporting Information). LIPG protein was detected in the supernatant of the senescent MCF‐7/NeuT (+dox), but not in control (−dox) cells, as the 68 kDa full‐length glycosylated form together with its 40 kDa cleavage product (Fig. [2](#ijc32138-fig-0002){ref-type="fig"} *d* and Fig. S3b, Supporting Information). This demonstrates that induction of LIPG transcription is followed by secretion of LIPG protein. Cytoplasmic LIPG protein levels were not increased by dox treatment (Figs. S3c‐S3d, Supporting Information). Thus, the inducible 68 kDa LIPG protein pool becomes readily secreted and is only detected in the extracellular fraction. No other members of the triglyceride lipase family were shown to be significantly up or downregulated upon NeuT induction in MCF7/NeuT cells (Table [S3](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information).

![Upregulation of LIPG in NeuT‐induced senescence contributes to lipid storage. (*a*) Representative Western blot showing expression of the NeuT oncogene in MCF‐7/NeuT cells treated with doxycycline (+dox) or untreated (−dox) at different time points. (*b*) Immunofluorescence illustrating senescence‐associated morphological changes and co‐induction of the reporter EGFP (*green*) upon dox treatment. The actin cytoskeleton was stained with rhodamine phalloidin (*red*); nuclei were stained with DAPI (*blue*); scale bar: 50 μm. (*c*) qPCR showing *LIPG* mRNA expression in MCF‐7/NeuT cells incubated with/without dox during the indicated time periods. Data represent the mean fold change in mRNA relative to time point 0 h ± SEM (n = 3). (*d*) Representative Western blot showing the 68 kDa LIPG protein and its 40 kDa cleavage product in supernatants of MCF‐7/NeuT cells (6d −/+ dox) incubated with heparin and densitometric quantification of the 68 kDa LIPG band from Western blots signals of three independent experiments (see also Fig. S3, Supporting Information). (*e*) Quantification of cellular triacylglycerides (TAG) in MCF‐7/NeuT cells cultivated for 7d with/without dox (time point of high *LIPG* expression). (*f*) *PLIN2* mRNA expression, analysed by qPCR as in (*c*). (*g*) Quantification of cellular triacylglycerides (TAG) in MCF‐7/NeuT cells cultivated for 6d with/without dox (±dox) in the presence or absence of 16 nM or 32 nM of the LIPG inhibitor GSK264220A. (*h*) Oil Red O (ORO) staining (*red*) to visualize lipid droplets in MCF‐7/NeuT cells treated for 6d‐7d ±dox in the presence or absence of the LIPG inhibitor GSK264220A (32 nM); *blue*: DAPI *green*: EGFP. Scale bar: 40 μm. All bar plots represent the mean ± SEM of three independent experiments. \*\**p* \< 0.01; \*\*\**p* \< 0.001 (for comparison between --dox and + dox incubated cells); ^\#^ *p* \< 0.05 (dox + GSK264220A‐incubated *vs*. dox only‐incubated cells); ^+^ *p* \< 0.05 (GSK264220A‐treated *vs*. untreated cells). *p‐*Values were calculated by unpaired two‐tailed Student\'s t‐test. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-901-g002){#ijc32138-fig-0002}

MCF‐7/NeuT cells examined 6d after NeuT induction (6d + dox) showed a threefold increase in TAG levels compared to control cells (6d‐dox) (Fig. [2](#ijc32138-fig-0002){ref-type="fig"} *e*). Consistently, *PLIN2* was also upregulated in MCF‐7/NeuT cells upon NeuT induction (Fig. [2](#ijc32138-fig-0002){ref-type="fig"} *f*). Blockage of LIPG activity with the LIPG inhibitor GSK264220A[21](#ijc32138-bib-0021){ref-type="ref"} significantly reduced intracellular TAG levels (Fig. [2](#ijc32138-fig-0002){ref-type="fig"} *g*) and LD accumulation (Fig. [2](#ijc32138-fig-0002){ref-type="fig"} *h*) in MCF‐7/NeuT cells. Thus, the increased triglyceride levels observed in NeuT‐induced senescence depend partially on LIPG activity.

*LIPG* expression is upregulated in oxidative stress conditions that compromise *de novo* fatty acid synthesis {#ijc32138-sec-0019}
--------------------------------------------------------------------------------------------------------------

Subsequent analyses aimed to identify stimuli that are able to upregulate LIPG. Upregulation of LIPG in MCF‐7/NeuT cells after induction of oncogenic HER2 (NeuT) suggested that LIPG could be a target of HER2. However, upregulation of *LIPG* by HER2 has not been reported in other studies. Therefore, we investigated LIPG expression in MCF‐7 cells stably transfected with wildtype HER2 or with a HER2 mutant containing a YVMA insertion in the kinase domain (A775_G776) that also enhances tyrosine kinase activity[13](#ijc32138-bib-0013){ref-type="ref"}, [22](#ijc32138-bib-0022){ref-type="ref"} and activates AKT, MEK1/2‐ERK1/2 and P38 signalling pathways as described for NeuT[11](#ijc32138-bib-0011){ref-type="ref"}, [12](#ijc32138-bib-0012){ref-type="ref"} (Fig. S4a, Supporting Information). qPCR analysis did not show an upregulation of *LIPG* in the HER2 insYVMA or the HER2 wildtype overexpressing MCF‐7 cells (Fig. S4b, Supporting Information). This suggests that *LIPG* expression is not generally triggered by HER2. Rather, *LIPG* expression in MCF‐7/NeuT cells may be the consequence of a metabolic reprogramming induced by the hyperactive NeuT.

One further hypothesis was that a compromised *de novo* lipogenesis may induce pathways of exogenous lipid uptake in breast cancer cells. Therefore, we pharmacologically inhibited *de novo* FAS in MCF‐7 cells by the acetyl CoA carboxylase (ACC) inhibitor 5‐tetradecyl‐oxy‐2‐furoic acid (TOFA)[23](#ijc32138-bib-0023){ref-type="ref"} and by the FASN inhibitor cerulenin (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *a*). Inhibition by TOFA but not by cerulenin resulted in a significant upregulation of *LIPG* mRNA (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *b*) in a concentration‐dependent manner (Fig. S5a, Supporting Information). This suggests that impairing ACC activity may determine *LIPG* upregulation. Silencing of the ACC catalytic subunit *ACACA via* transfection with siRNA (Fig. S5b, Supporting Information) also resulted in a slight upregulation of *LIPG* mRNA (Fig. S5c, Supporting Information) and supported the hypothesis that LIPG compensates a diminished *de novo* FAS.

![LIPG becomes upregulated upon cellular stress‐mediated inhibition of *de novo* fatty acid synthesis (FAS). (*a*) Schematic illustration of the initial steps of *de novo* FAS, regulation of acetyl‐CoA carboxylase (ACC) by AMPK, and pharmacological inhibition by TOFA and cerulenin. (*b*) qPCR analysis of *LIPG* mRNA expression in MCF‐7 cells incubated for 24 h with 6 μM TOFA (n = 4). (*c*) Representative Western blot showing protein levels of TXNRD1 in MCF‐7/NeuT cells incubated with/without dox at the indicated time points. (*d*) TBARS assay showing levels of ROS in cellular extracts of MCF‐7/NeuT cells incubated 7d with/without dox (n = 3). (*e*) Representative Western blots showing the phosphorylation status of AMPK in MCF‐7/NeuT cells (6d with/without dox) and densitometric quantification of the ratios of phospho‐AMPK (p‐AMPK) and total‐AMPK (t‐AMPK) to β‐actin from Western blot signals of three independent experiments. (*f*) Representative Western blot showing the phosphorylation status of ACC in MCF‐7/NeuT cells (6d with/without dox) and densitometric quantification of the ratios of phospho‐ACC (p‐ACC) and total‐ACC (t‐ACC) to calnexin from Western blot signals of three independent experiments. Bars indicate mean ± SEM. \*\*\**p* \< 0.001; \**p* \< 0.05, unpaired two‐tailed Student\'s t‐test. (*g*) Mitochondrial integrity of cells transfected with LIPG or empty vector (EV), fed with LIPG substrate (PC) and subsequently treated with TOFA to block fatty acid synthesis. The bar diagrams represent the mean ± SEM of three independent experiments. \*\*\**p* \< 0.001, unpaired two‐tailed Student\'s t‐test.](IJC-145-901-g003){#ijc32138-fig-0003}

Accordingly, we next studied whether ACC is inhibited in senescent MCF‐7/NeuT cells. Different stress conditions, including reactive oxygen species (ROS), activate the AMP‐kinase (AMPK), which in turn phosphorylates and inhibits ACC (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *a*).[24](#ijc32138-bib-0024){ref-type="ref"}, [25](#ijc32138-bib-0025){ref-type="ref"} An increase in ROS generation has been demonstrated in MCF‐7/NeuT and other models of oncogene‐induced senescence (OIS),[11](#ijc32138-bib-0011){ref-type="ref"}, [26](#ijc32138-bib-0026){ref-type="ref"} including lipid peroxides[11](#ijc32138-bib-0011){ref-type="ref"} as well as superoxide anions and hydrogen peroxide.[26](#ijc32138-bib-0026){ref-type="ref"} Thus, as expected, we confirmed the previously observed upregulation of thioredoxin reductase (TXNRD1)[11](#ijc32138-bib-0011){ref-type="ref"} (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *c*) and increased levels of thiobarbituric acid reactive substances (TBARS) (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *d*) as measures of ROS‐mediated lipid peroxidation and demonstrated phosphorylation (activation) of AMPK (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *e*) and phosphorylation (inhibition) of ACC (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *f*) in senescent MCF‐7/NeuT cells. Together, these data suggest that oxidative stress is a biological context in which fatty acid synthesis is inhibited, and the resulting compensatory induction of LIPG occurs.

LIPG protects from mitochondrial dysfunction under metabolic stress conditions {#ijc32138-sec-0020}
------------------------------------------------------------------------------

Published studies have shown that fatty acids derived from intracellular LD‐lipolysis support cells during starvation,[27](#ijc32138-bib-0027){ref-type="ref"} and are delivered to mitochondria.[28](#ijc32138-bib-0028){ref-type="ref"} This is supported by the association of PLIN2‐positive LDs with mitochondria.[28](#ijc32138-bib-0028){ref-type="ref"}, [29](#ijc32138-bib-0029){ref-type="ref"} We confirmed the relevance of LDs in cell survival by monitoring cell growth during the course of a feeding‐starvation experiment. As shown in Figure S6a, Supporting Information, cells fed with OA had a survival advantage during starvation. To study a possible contribution of LDs in mitochondrial integrity, tetramethylrhodamine methyl ester perchlorate (TMRE), which only accumulates in functional mitochondria with transmembrane potential (Δψm), was monitored. TMRE levels were higher in cells that had lipid stores available during starvation (Fig. S6b, Supporting Information).

We next investigated whether LIPG‐mediated lipid supply confers a survival advantage to cells. To this end we explored whether LIPG‐mediated LD accumulation supports mitochondria under conditions of compromised FAS. When blocking *de novo* FAS with TOFA in LIPG‐OE and EV transfected cells fed with PC‐OA, mitochondrial integrity was higher in LIPG overexpressing cells than in control cells (Fig. [3](#ijc32138-fig-0003){ref-type="fig"} *g*), supporting that LIPG provides a survival advantage once endogenous FAS is limited.

Upregulation of *LIPG* by CoCl~2~ contributes to lipid storage and adaptation to oxidative stress and is abrogated by ROS scavengers {#ijc32138-sec-0021}
------------------------------------------------------------------------------------------------------------------------------------

To investigate further oxidative stress stimuli, we used the hypoxia‐mimicking and ROS‐inducing agent cobalt chloride (CoCl~2~). Exposure of MCF‐7 cells to CoCl~2~ resulted in AMPK phosphorylation in a concentration‐dependent manner (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *a*). Although phosphorylation of the AMPK‐target ACC was not increased, total ACC protein levels decreased significantly (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *b*) in agreement with studies showing that AMPK can also regulate ACC at the transcriptional level, repressing its promoter activity *via* NRF‐1.[30](#ijc32138-bib-0030){ref-type="ref"} *LIPG* was upregulated more than fivefold at high concentrations of CoCl~2~ (0.9 mM) (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *c*). In line with the ROS‐generating effect of CoCl~2~, which has been reported to increase superoxide production by mitochondria,[31](#ijc32138-bib-0031){ref-type="ref"} *TXNRD1* mRNA was also induced (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *c*). CoCl~2~ also led to the upregulation of *PLIN2* mRNA (Fig. 4*c*) and to increased levels of TAG and LDs (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *d*). The contribution of LIPG to CoCl~2~‐triggered lipid storage was demonstrated by showing restoration of basal TAG levels and concomitant reduction of the amount of LDs (Figs. [4](#ijc32138-fig-0004){ref-type="fig"} *e* and 4*f*) upon inhibition of LIPG with GSK264220A. Furthermore, also knockdown of LIPG, which showed \>80% reduction of LIPG mRNA and loss of the secreted 68 kDa LIPG protein led to a decreased cellular TAG content (Figs. S7a‐S7d, Supporting Information). Moreover, it prevented upregulation of LIPG upon exposure to CoCl~2~ (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *g*) and led to a significant decrease in cell viability (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *h*), demonstrating a role for LIPG in adaptation to oxidative stress.

![Upregulation of *LIPG* by CoCl~2~ contributes to lipid storage and adaptation to oxidative stress and is abrogated by ROS scavengers. (*a*) Representative Western blot showing AMPK phosphorylation in MCF‐7 cells exposed to different concentrations of CoCl~2~ for 24 h and densitometric quantification of the ratio (phospho‐AMPK/total‐AMPK) from Western blot signals of three independent experiments. (*b*) Representative Western blot showing ACC phosphorylation in MCF‐7 cells exposed to 0.89 mM of CoCl~2~ for 24 h and densitometric quantification of the ratios (p‐ACC and t‐ACC to calnexin) from Western blot signals of three independent experiments. (*c*) qPCR analysis showing *LIPG*, *PLIN2* and *TXNRD1* mRNA levels in MCF‐7 cells treated for 24 h with the indicated concentrations of CoCl~2~. (*d*) Quantification of triacylglycerides (TAG) in MCF‐7 cells exposed for 24 h to the indicated concentrations of CoCl~2~ and visualization of lipid droplets by BODIPY 493/503 staining (*green*) in 0.89 mM CoCl~2~‐treated and untreated (FM) MCF‐7 cells; *red*: Rhodamine phalloidin staining of the actin cytoskeleton; *blue*: DAPI. Scale bars: 20 μm. (*e*) Visualization of lipid droplets in MCF‐7 cells exposed to 0.89 mM CoCl~2~ for 24 h in the presence or absence of 16 nM or 32 nM of the LIPG inhibitor GSK264220A. *red*: Rhodamine phalloidin staining of the actin cytoskeleton; *blue*: DAPI. Scale bars: 40 μm. (*f*) Quantification of TAGs in CoCl~2~‐treated MCF‐7 cells in the presence or absence of 16 nM or 32 nM GSK264220A (duplicates are shown). (*g*) qPCR analysis showing LIPG mRNA levels in MCF‐7 cells after transfection with scrambled si‐RNA as a negative control (si‐neg) and two different si‐RNA oligos targeting LIPG (si‐LIPG‐A and si‐LIPG‐B), compared to FM (full media, non‐transfected control) and Lipo (Lipofectamine only, mock‐transfected) and subsequent 24 h‐exposure to CoCl~2~. (*h*) Cell Titer Blue viability assay showing cell survival after three more days under the same conditions as in (*g*). Bar diagrams represent the mean ± SEM of three independent experiments; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\*\**p* \< 0.0001 for comparison of each of the siRNAs with the negative control (scramble, si‐neg). ^\#\#\#\#^ *p* \< 0.0001; ^\#\#\#^ *p* \< 0.001 for comparisons to untreated cells (FM). *p*‐Values were calculated by unpaired two‐tailed Student\'s t‐test. (*i*) Representative Western blot showing AMPK phosphorylation in MCF‐7 cells exposed to 0.5 mM or 0.89 mM CoCl~2~ alone or in the presence of 20 mM NAC for 24 h and densitometric quantification of the ratio (phospho‐AMPK/total‐AMPK) from Western blot signals of three independent experiments. (*j*) qPCR analysis showing mRNA levels of *LIPG*, *PLIN2* and *TXNRD1* in MCF‐7 cells exposed to CoCl~2~ in the presence or absence of 20 mM NAC. (*k*) Quantification of cellular TAGs in MCF‐7 cells exposed to CoCl~2~ in the presence or absence of NAC. (*l*) Visualization of lipid droplets by BODIPY 493/503 (*green*) in CoCl~2~‐treated in MCF‐7 cells in the presence or absence of 20 mM NAC; *red*: Rhodamine phalloidin staining of the actin cytoskeleton; *blue*: DAPI Scale bars: 40 μm. All bar diagrams represent the mean ± SEM of three independent experiments. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001 (CoCl~2~‐treated *vs*. untreated cells); ^\#^ *p* \< 0.05; ^\#\#^ *p* \< 0.01; ^\#\#\#^ *p* \< 0.001 (NAC‐treated or GSK264220A‐treated *vs*. untreated cells). *p*‐Values were calculated by unpaired two‐tailed Student\'s t‐test. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](IJC-145-901-g004){#ijc32138-fig-0004}

Because CoCl~2~ also acts as a hypoxia mimetic, we explored the possible upregulation of *LIPG* by hypoxia. We observed no hypoxia‐specific upregulation of *LIPG* (Fig. S8, Supporting Information), rather a cell density‐dependent downregulation. A similar pattern was shown for *TXNRD1*. Hypoxia‐dependent upregulation of *PLIN2* accompanied the increased expression of the hypoxia marker *VEGF* (Fig. S8, Supporting Information), which altogether suggests a hypoxia‐triggered LD accumulation in a LIPG‐independent manner. Incubation of cells with H~2~O~2~ also led to a slight but significant induction of *LIPG* and *TXNRD1* (Fig. S9a, Supporting Information), and treatment with rotenone, which results in superoxide generation, led to an even higher upregulation of *LIPG* and *TXNRD1* (Fig. S9b, Supporting Information), again reinforcing the link between LIPG and oxidative stress.

Altogether, these results strongly support the concept that oxidative stress upregulates *LIPG* as an alternative lipid supply pathway in breast cancer cells where *de novo* FAS is compromised by ROS.

In view of these results, we tested the ability of the ROS scavenger N‐acetyl‐cysteine (NAC) to counteract the effects of CoCl~2~. Addition of NAC abrogated CoCl~2~‐triggered phosphorylation of AMPK (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *i*). Furthermore, both *LIPG* and *PLIN2* induction were prevented in the presence of NAC (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *j*). *TXNRD1* expression also decreased to control levels, confirming efficient scavenging of ROS (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *j*). Moreover, TAG levels were normalized upon NAC treatment (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *k*) and no accumulation of LDs was observed (Fig. [4](#ijc32138-fig-0004){ref-type="fig"} *l*). Supplementing CoCl~2~‐treated MCF‐7 cells with GSH partially prevented *LIPG* and *TXNRD1* upregulation as well (Fig. [S10](#ijc32138-supitem-0001){ref-type="supplementary-material"}, Supporting Information). Hence, counteracting oxidative stress prevents the upregulation of *LIPG* as well as LIPG‐mediated lipid storage.

In senescent MCF‐7/NeuT cells neither NAC nor the superoxide scavenger Mn(111) tetrakis 1‐methyl 4‐pyridyl porphyrin pentachloride (MnTMPyP) nor diphenyleneiodonium chloride (DPI), an inhibitor of NADPH oxidase‐like flavoenzymes, which efficiently scavenged ROS in other models of OIS,[32](#ijc32138-bib-0032){ref-type="ref"}, [33](#ijc32138-bib-0033){ref-type="ref"} counteracted oxidative stress (Figs. [S11a‐S11c](#ijc32138-supitem-0001){ref-type="supplementary-material"}, Supporting Information). Accordingly, *LIPG* and *TXNRD1* levels remained high (Figs. [S11a‐S11c](#ijc32138-supitem-0001){ref-type="supplementary-material"}, Supporting Information). Only the inhibition of the tyrosine kinase activity of HER2/NeuT with lapatinib markedly decreased *LIPG* levels and slightly diminished *TXNRD1* mRNA. (Fig. [S11](#ijc32138-supitem-0001){ref-type="supplementary-material"}d, Supporting Information). Thus, oxidative stress caused by the constitutively active NeuT in MCF‐7/NeuT cells cannot be efficiently scavenged by conventional antioxidants. Only by antagonizing its tyrosine kinase activity was LIPG upregulation inhibited. A striking observation was the strong upregulation of *LIPG*, *PLIN2*, and *TXNRD1* in control cells (−dox, non‐senescent) upon treatment with DPI and MnTMPyp. This suggests that *LIPG* upregulation also occurs in response to reductive stress, and is thus responsive to general disturbances in the cellular redox state.

High *LIPG* expression associated with shorter metastasis‐free survival in human node‐negative breast cancer {#ijc32138-sec-0022}
------------------------------------------------------------------------------------------------------------

Recent reports indicate the relevance of LIPG in human breast cancer.[9](#ijc32138-bib-0009){ref-type="ref"}, [10](#ijc32138-bib-0010){ref-type="ref"} However, discrepancies between the studies with regard to LIPG expression remained unclarified. We analysed LIPG gene and protein expression in our previously established breast cancer cohort (Mainz cohort, GSE11121) of node‐negative breast cancer patients who were untreated in both neoadjuvant and adjuvant settings.[34](#ijc32138-bib-0034){ref-type="ref"}, [35](#ijc32138-bib-0035){ref-type="ref"} *LIPG* mRNA (Affymetrix probeset 219181_at) revealed a bimodal expression distribution, where a small subset of tumours expressed high *LIPG* levels (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *a* and Fig. [S12](#ijc32138-supitem-0001){ref-type="supplementary-material"}a, Supporting Information). To validate this finding, we explored additional, publicly available breast cancer cohorts. A similar distribution, with only a relatively small subset of tumours expressing high levels of *LIPG*, was also observed in three publicly available node‐negative, untreated breast cancer cohorts, as well as in several datasets of patients who received adjuvant or neoadjuvant therapy (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *a* and Figs. [S12a‐S12c](#ijc32138-supitem-0001){ref-type="supplementary-material"}, Supporting Information). Comparing *LIPG* levels analysed by Affymetrix gene array and qPCR for a selection of tumours from the Mainz cohort, for which RNA was available, revealed a strong correlation between the two methods (Pearson r = 0.96, *p* \< 0.001) (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *b*) and excluded that the observed expression pattern was due to probeset‐dependent effects. Moreover, also in the TCGA breast cancer dataset, including data from 1,125 specimens analysed with RNA sequencing (<https://tcga-data.nci.nih.gov>/) was only a small subset of breast tumours with high LIPG expression observed (Fig. [S13](#ijc32138-supitem-0001){ref-type="supplementary-material"}a, Supporting Information), further indicating that high *LIPG* expression is rare in human breast cancer.

![Expression of LIPG in human breast cancer and association with metastasis‐free survival. (*a*) Box plots showing the distribution of *LIPG* mRNA expression in 18 breast cancer datasets, including node‐negative, untreated cohorts as well as cohorts of patients who had received adjuvant (tamoxifen (TAM) only), hormonal and/or chemotherapy and/or both and/or unknown treatment (adjuvant\*) and neoadjuvant therapy. (*b*) Correlation of Affymetrix and qPCR results with Pearson correlation r = 0.9623, *p* \< 0.001. (*c*) Kaplan--Meier plots showing association of high *LIPG* expressing tumours (4 out of 200 tumours using the cut‐off log2 ≥ 98th percentile) with shorter metastasis free survival (MFS) in the Mainz cohort (GSE11121) (left) and in the combined cohort of untreated patients (16 out of 824 tumours, consisting of GSE11121, GSE2034, GSE5327, GSE6532 and GSE7390) (right). p\*: *p*‐Value of the permutation test; p: *p*‐Value from the log‐rank test. (*d*) top: Representative images of LIPG IHC of 259 node‐negative breast carcinomas of the tissue microarray (TMA); scale bars: 100 μm; (*d*) bottom, left: barplot showing LIPG protein expression distribution in the TMA; (*d*) bottom, middle: Kaplan--Meier plot of the association of LIPG protein expression (as determined by IHC in the tissue array) with metastasis free survival (MFS). p: *p*‐Value of the log‐rank test; (*d*) bottom right: Association between *LIPG* mRNA (Affymetrix data) and LIPG protein expression (IHC data) in the Mainz cohort. (*e*) Scatter plots displaying the relationship between expression of *LIPG* and *PLIN2*, and (*f*) between expression of *LIPG* and *TXNRD1* in the combined cohort of node‐negative untreated breast cancer patients. The dashed lines represent the cut‐off for *LIPG* (log2 ≥ 98th percentile) and the median for *PLIN2* and *TXNRD1*. The number of samples in each quadrant is shown. P: *p*‐Value from Fisher\'s exact test. (*g*) Kaplan--Meier plots showing association of *LIPG* and *PLIN2* and (*h*) *LIPG* and *TXNRD1* with MFS in each of the patient subgroups stratified according to the aforementioned cutpoints. *p*‐Values of the log‐rank test for the pairwise comparisons are shown in the corresponding tables. (*i*) Proposed model: Adaptation of tumour cells to oxidative stress by LIPG: Under normal conditions cells synthesise fatty acids (FA) *de novo via* FAS, which consumes NADPH. Basal levels of LIPG may supply FA as well. Upon oxidative stress, activation of AMPK triggers a metabolic reprogramming that turns down ATP/NADPH consuming pathways such as the *de novo* FAS, enabling NADPH‐dependent protein repair *via* TXNRD1/TXN. Upregulation of *LIPG* along with *PLIN2* and *TXNRD1* occurs. Secreted LIPG provides FA that become stored as triglycerides in PLIN2‐coated lipid droplets. These support mitochondrial integrity, possibly *via* lipid remodeling, and thus protect against ROS.](IJC-145-901-g005){#ijc32138-fig-0005}

In the Mainz cohort, higher *LIPG* expression was significantly associated with shorter MFS in a univariate Cox analysis (Table [S4](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information). The small subset of patients with tumours expressing high *LIPG* levels showed significantly shorter MFS, illustrated by a Kaplan--Meier plot (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *c*, left panel). In contrast, a recent study[9](#ijc32138-bib-0009){ref-type="ref"} investigating LIPG protein levels in a TMA of 439 breast cancer patients using immunohistochemistry (IHC), reported high and ubiquitous expression of LIPG, and no association with outcome. Interestingly, when a TMA including the patients of the Mainz cohort was immunostained using the same antibody as Slebe *et al.,* [29](#ijc32138-bib-0029){ref-type="ref"} broad cytoplasmic LIPG expression was also observed (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *d*, upper and lower left panel), and there was no association of LIPG positivity with clinicopathological parameters (Table [S5](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information) or MFS (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *d*, lower middle panel). Importantly, we observed no correlation between cytoplasmic LIPG protein staining by IHC with this antibody and mRNA levels (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *d*, lower right panel). This is in line with the results obtained *in vitro*, showing that not cytoplasmic but secreted LIPG reflects mRNA levels.

To further validate the association of high *LIPG* mRNA expression with MFS, three additional node‐negative, untreated breast cancer datasets (GSE2034 n = 286; Transbig: GSE6532 n = 84 and GSE7390 n = 196; and GSE5327 n = 58) were analysed. As observed in the Mainz cohort, a significantly shorter MFS was observed for high *LIPG*‐expressing tumours in the Transbig cohort (Table [S4](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information), as well as in the combined node‐negative dataset (Table [1](#ijc32138-tbl-0001){ref-type="table"}), illustrated by Kaplan--Meier plots (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *c*, right panel). In the combined node‐negative dataset, high *LIPG* expression correlated with ER negative status (*p* \< 0.001) and high tumour grade (P = 0.014) (Table [S6](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information). Interestingly, in a multivariate Cox analysis, *LIPG* was associated with worse prognosis, independent of grade, stage, age, ER‐, and HER2 status (Table [1](#ijc32138-tbl-0001){ref-type="table"}).

###### 

Univariate and multivariate Cox analysis showing association of *LIPG* mRNA expression with metastasis free survival (MFS) in a combined cohort of node‐negative untreated breast cancer patients (n = 824) consisting of the GSE11121 (n = 200), GSE2034, (n = 286), Transbig (GSE6532 and GSE7390, n = 280) and GSE5327 (n = 58) cohorts

  Combined cohort                                                 
  ------------------ ------ --------- ------------ ------ ------- ------------
                     HR     *p*       95% CI       HR     *p*     95% CI
  **Age**                                                         
  \<50 years         1.00                          1.00           
  ≥50 years          1.01   0.976     0.71--1.43   1.02   0.922   0.71--1.47
  **pT stage**                                                    
  *Stage I*          1.00                          1.00           
  *Stage II + III*   1.32   0.114     0.93--1.87   1.18   0.370   0.82--1.71
  **Grade**                                                       
  Grade 1 + 2        1.00                          1.00           
  Grade 3            1.93   \<0.001   1.36--2.75   1.70   0.013   1.12--2.58
  **ER status**                                                   
  *Negative*         1.00                          1.00           
  *Positive*         0.74   0.031     0.56--0.97   1.00   0.987   0.64--1.57
  **HER2 status**                                                 
  *Negative*         1.00                          1.00           
  *Positive*         1.13   0.468     0.81--1.58   1.20   0.465   0.74--1.93
  *LIPG*             1.59   0.002     1.18--2.15   1.95   0.002   1.26--2.99

Abbreviations: HR, hazard ratio; *p*, *p*‐value (unadjusted); CI, confidence interval.

Next, analysing the association of *LIPG* with MFS in more heterogeneous patient populations, including also node‐positive patients and patients who received adjuvant treatment with hormonal drugs and/or chemotherapy revealed a significant association of high *LIPG* expression with worse outcome in one dataset, but was not confirmed to be a general feature of human breast cancer (Figs. S12 and S13, Supporting Information). The lack of association with MFS in tamoxifen‐treated breast cancers is however not surprising, since it is in line with our findings that *LIPG* was associated with ER‐negative status (Table [S6](#ijc32138-supitem-0002){ref-type="supplementary-material"}, Supporting Information). That no significant association was observed between high *LIPG* expression and MFS in the datasets where all, or the majority of patients were treated with adjuvant chemotherapy might be due to factors related to the chemotherapy response being more important for metastatic recurrence in an adjuvantly treated patient population.

The previously described *in vitro* experiments demonstrated that LIPG supports lipid droplet formation and mitochondrial integrity under conditions of oxidative stress. These findings were supported in the combined node‐negative dataset where the majority of *LIPG*‐high tumours also expressed the lipid droplet marker *PLIN2*, and the oxidative stress marker *TXNRD1* at levels above the median (Figs. [5](#ijc32138-fig-0005){ref-type="fig"} *e* and 5*f*). Both *PLIN2* (209122_at) and *TXNRD1* (201266_at) were also significantly associated with shorter MFS in the combined node‐negative dataset in a univariate Cox analysis (Tables S7 and S8, Supporting Information), as illustrated by Kaplan--Meier plots (Fig. [S14](#ijc32138-supitem-0001){ref-type="supplementary-material"}a, Supporting Information) and in previous work.[11](#ijc32138-bib-0011){ref-type="ref"} However, for the combined node‐negative dataset, adding *LIPG* to the model that included *PLIN2* or *TXNRD1* corresponded to a significant increase in the likelihood ratio statistic (Fig. [S14](#ijc32138-supitem-0001){ref-type="supplementary-material"}b, Supporting Information). This shows that including *LIPG* as a variable adds a significant amount of prognostic information to the model, in addition to *PLIN2* or *TXNRD1,* and is not simply a marker of lipid accumulation. As illustrated by Kaplan--Meier plots, survival was worse when both *PLIN2* and *LIPG* expression were high (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *g*), with similar results being obtained for *LIPG* and *TXNRD1* (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *h*).

In summary, high *LIPG* mRNA expression occurred in a small subset of breast tumours, primarily high grade and ER‐negative, and was associated with shorter MFS in node‐negative, systemically untreated tumours. Co‐expression of *LIPG* mRNA with *TXNRD1*, and *PLIN2* suggests a role for LIPG in the context of oxidative stress and lipid droplet accumulation, while simultaneously supporting the results obtained *in vitro*.

Discussion {#ijc32138-sec-0023}
==========

The present study has uncovered two new aspects of the role of LIPG in breast cancer: First, high LIPG expression, which provides an alternative source of FFA to *de novo* synthesis *via* extracellular lipolysis, is particularly relevant under oxidative stress conditions, when lipogenesis is inhibited *via* AMPK. In this context, LDs accumulated by the action of LIPG fuel and protect mitochondria from ROS, possibly superoxide (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *i*). Thus, high compensatory LIPG expression may facilitate tumour cell survival under oxidative stress conditions, which is supported by increased cell death in LIPG‐depleted cells. Second, high *LIPG* mRNA expression is significantly associated with shorter MFS of node‐negative, adjuvantly untreated breast cancer. Therefore, LIPG appears to contribute to unfavourable prognosis, enabling adaptation to oxidative stress.

The different experimental conditions in which we observed *LIPG* upregulation, OIS, chemical hypoxia by CoCl~2~, and exposure to H~2~O~2~ and rotenone are characterized by severe oxidative stress. This strongly supports oxidative stress as a biological context in which high LIPG expression is required for survival of tumour cells. In all cases, increased mRNA levels of *TXNRD1* accompanied the upregulation of *LIPG* expression, indicating an enhanced demand for NADPH‐dependent antioxidant pathways. We also showed in two cases that oxidative stress led to a negative regulation of *de novo* FAS *via* AMPK. This mechanism of repression of FAS has been reported to take place under conditions of oxidative stress to avoid consumption of NADPH[36](#ijc32138-bib-0036){ref-type="ref"} and was also demonstrated to occur in a model of Ras oncogene‐induced senescence in human fibroblasts.[37](#ijc32138-bib-0037){ref-type="ref"} Since *LIPG*‐mediated lipid supply *via* extracellular lipolysis is NADPH‐independent, we propose that this alternative pathway reduces NADPH consumption, which then is available as a cofactor of *TXNRD1* for protein repair (Fig. [5](#ijc32138-fig-0005){ref-type="fig"} *i*).

It is noteworthy that although hypoxia‐induced oxidative stress has been reported to upregulate a pathway of exogenous FFA uptake due to a compromised *de novo* FAS[38](#ijc32138-bib-0038){ref-type="ref"} our study showed that *LIPG* is not upregulated by hypoxia (1%O~2~). This suggests that LIPG is not essential in hypoxia‐triggered lipid accumulation under these conditions.

Our findings also indicate that FFAs supplied by LIPG contribute to the formation of LDs. Lipid droplets have recently been reported to protect cells against ROS.[38](#ijc32138-bib-0038){ref-type="ref"}, [39](#ijc32138-bib-0039){ref-type="ref"} One potential mechanism is the redirection of ROS‐susceptible polyunsaturated fatty acids from the cell membrane to LDs where they are shielded from peroxidation.[39](#ijc32138-bib-0039){ref-type="ref"} Interestingly, our previous study showed that senescent MCF‐7/NeuT cells underwent a glycerophospholipid remodelling towards increased saturation of acyl chains, thereby decreasing susceptibility to peroxidation.[8](#ijc32138-bib-0008){ref-type="ref"} In this context, LIPG‐triggered LDs may support membrane lipid repair, preserving mitochondrial integrity from ROS. Thus, in contrast to a reported role for LIPG in fuelling proliferation,[9](#ijc32138-bib-0009){ref-type="ref"} the present results showed a cell proliferation‐independent and previously unrecognized role of LIPG in enabling protective LDs accumulation in tumour cells. In agreement with this hypothesis, breast tumours expressing high levels of *LIPG* also expressed high levels of the oxidative stress marker *TXNRD1*, and the lipid droplet marker *PLIN2* and MFS time was shorter in *PLIN2* and *LIPG*‐high as well as in *TXNRD1* and *LIPG*‐high subgroups compared to only‐*TXNRD1*‐high or only‐*PLIN2*‐high subgroups. The finding that LIPG significantly improved the likelihood ratio statistics compared to models with *PLIN2* or *TXNRD1* alone demonstrates the independent contribution of *LIPG* to worse prognosis.

Our findings that high *LIPG* mRNA expression is restricted in breast cancer and significantly associated with worse survival apparently contradict the study reporting a broad expression and no significant association between IHC‐determined LIPG and survival.[9](#ijc32138-bib-0009){ref-type="ref"} When we performed IHC of our TMA, using the same LIPG antibody as Slebe and co‐workers,[9](#ijc32138-bib-0009){ref-type="ref"} we also found no association of cytoplasmic LIPG positivity with prognosis in our cohort, but also no association of cytoplasmic LIPG positivity with LIPG transcript levels. Importantly, our *in vitro* studies demonstrated that *LIPG* mRNA levels only correlated with those of extracellular LIPG protein and not with those of cytoplasmic LIPG, which may account for the remaining non‐secreted LIPG pool. Since the extracellular localization enables LIPG to access serum lipoproteins for lipid supply we conclude that the actively secreted LIPG protein, and thus, as a surrogate, *LIPG* transcript levels represent a more relevant measure for analysing the association with tumour prognosis. Notably, only *via* this approach could LIPG\'s association with worse prognosis be uncovered. The initial observation of *LIPG*'s association with shorter MFS made in our own cohort was subsequently confirmed in two additional publicly available breast cancer cohorts. Moreover, a significant association of high *LIPG* with grade 3 and with negative ER status was observed. The latter was in agreement with a much higher LIPG expression in the triple negative cell lines MDA‐MB231 und MDA‐MB468, and in the ER‐/HER2+ cell lines HCC1954 and SKBR3 than in the ER‐positive cell lines MCF‐7, T47D and BT474. The lack of significant association of high *LIPG* with HER2 status observed in tumours and in the cell lines was consistent with our finding that *LIPG* is not upregulated by HER2 overexpression in cultured breast cancer cells. Finally, our findings are in line with a recent study reporting expression and a role for LIPG in metastasis of human basal‐like triple‐negative breast cancer.[10](#ijc32138-bib-0010){ref-type="ref"}

In summary, integrating our *in vitro* experimental data and our analysis of *LIPG*‐expressing tumours led to the concept that *LIPG* upregulation in cancer cells under oxidative stress enables survival when the lipid requirement of the cell exceeds its capacity to synthesize fatty acids *de novo*, or when *de novo* lipogenesis is repressed by ROS. Although cancer cells have generally high ROS levels, these levels further increase under a harsh tumour microenvironment, nutrient deprivation or upon matrix detachment.[40](#ijc32138-bib-0040){ref-type="ref"}, [41](#ijc32138-bib-0041){ref-type="ref"} Thus, metabolic adaptation to these conditions *via* LIPG upregulation may be a crucial event determining adverse progression, as suggested by the observation that high *LIPG* expression is associated with shorter MFS.
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**Figure S1** LIPG mRNA expression in breast cancer cell lines.

\(a\) qPCR showing mRNA levels of LIPG in MCF‐7, MDA‐MB‐231, MDA‐MB‐468 cells (top), and SKBR3, HCC1954, BT474 and T47D (bottom). LIPG expression level in MCF‐7 cells was taken as a reference. As an endogenous control, UBC (ubiquitin C protein) was used. The bars represent the mean ± SEM (n = 3). (b) Western blots of cell lysates (intracellular fraction) and supernatants (extracellular fraction) obtained from cell cultures. For capturing the extracellular LIPG, including the secreted and cell surface‐associated LIPG fraction, cells were treated over night with 25 U/ml heparin and supernatants were collected. Western blots are representative from three experiments. An antibody directed against the N‐terminus of LIPG (ab24447, Abcam) was used.

**Figure S2.** LIPG overexpression and substrate dependency in transfected MCF‐7 cells.

\(a\) qPCR analysis showing levels of *LIPG* mRNA in MCF‐7 cells transfected with empty‐vector (EV) or with a LIPG overexpression vector (LIPG‐OE) compared to non‐transfected cells (full medium control, FM). (b) Representative Western blots showing expression of LIPG in the intracellular and extracellular cell fraction of full media control (FM), negative control (only transfection reagent, NC), empty vector (EV) and LIPG overexpressing (OE) cells. PS: Precision Plus Protein™ Dual Color Standard; MM: MagicMark™ XP Western Protein Standard. (c) Immunofluorescence of transfected cells with an anti‐FLAG antibody targeting the LIPG‐FLAG fusion protein encoded by the LIPG overexpression construct (*red*); *blue*: DAPI; Scale bars: 50 μm. (d) Quantification of triglycerides (TAGs) in extracts of MCF‐7 cells transfected for 48 h with empty vector (EV) and LIPG overexpressing vector (LIPG‐OE) and incubated for further 48 h in the presence of 800 μg HDL, compared to non‐transfected, full medium‐control (FM) cells. (e) MCF‐7 cells were incubated for 48 h in the presence of oleic acid complexed to bovine‐serum albumin BSA (OA/BSA) or BSA‐only (BSA).. Intracellular triacylglyceride (TAG) levels were quantified with the triglyceride quantification assay kit. RFU: relative fluorescence units normalized to cellular protein levels. *PLIN2* mRNA levels were analysed by qPCR. Lipid droplets were visualized with BODIPY 493/503 staining (green). Nuclei were stained with DAPI (blue). Bar diagrams represent the mean ± SEM (n = 3). \*\*\*P \< 0.001. P‐value was calculated by unpaired two‐tailed Student\'s t‐test.

**Figure S3.** *LIPG* mRNA upregulation in senescent MCF‐7/NeuT cells results in secretion of LIPG protein**.** (a) qPCR analysis showing a 15‐fold increase in levels of *LIPG* mRNA in MCF‐7/NeuT cells incubated with dox. (b) Representative Western blot showing levels of mature 68 kDa LIPG and its 40 kDa cleaved N‐terminal fragment in the supernatant of MCF‐7/NeuT cells treated with/without dox and densitometric quantification of Western blot signals of three independent experiments. (c) Representative Western blot of LIPG in the corresponding cellular lysates showing the remaining cytoplasmic pool of LIPG. For the strongest three signals (57 kDa, 48 kDa and 42 kDa), which could correspond to the non‐mature unglycosylated LIPG (57 kDa) and other uncharacterized splice variants, densitometric quantification of Western blot signals is shown for three independent experiments. (d) Immunofluorescence of fixed MCF‐7/NeuT cells, treated with/without Triton X‐100 for permeabilisation, showing no increase in cytoplasmic LIPG immunoreactivity (*red*) upon dox treatment; *blue*: DAPI. Scale bar: 50 μm. Bar diagrams represent the mean ± SEM (n = 3). \*\*\*\*P \< 0.0001. P‐value was calculated by unpaired, two‐tailed Student\'s t test.

**Figure S4.** *LIPG* mRNA upregulation is not driven by HER2 overexpression

\(a\) Western blots showing phosphorylation of AKT, ERK1/2 and P38 in parental MCF‐7 cells and in MCF‐7 cells stably transfected with wildtype Her2 and the mutant insYVMAHer2. (b) *LIPG* mRNA expression level in the three cell lines determined by qPCR. *LIPG* expression in parental MCF‐7 cells was taken as a reference. As an endogenous control UBC (ubiquitin C protein) was used. The bars represent the mean ± SEM (n = 6).

**Figure S5**. Pharmacological inhibition and silencing of ACC lead to upregulation of *LIPG* expression. (a) qPCR analysis of LIPG mRNA expression in MCF‐7 cells incubated for 24 h with TOFA or cerulenin at the indicated concentrations. The bar diagrams represent the mean ± SEM of two independent experiments. (b) left: qPCR analysis showing ACACA mRNA levels in MCF‐7 cells after transfection with scrambled si‐RNA as a negative control (si‐neg) and two different si‐RNA oligos targeting ACACA (si‐ACC‐A and si‐ACC‐B), compared to FM (full media, non‐transfected control) and Lipo (Lipofectamine only, mock‐transfected). Right: Representative Western blot showing ACC protein levels as well as Calnexin as a loading control, and densitometric quantification of the ratio (ACC/Calnexin) from Western blot signals of three independent experiments. (c) qPCR analysis showing LIPG mRNA levels in the same samples as in (b). Bar diagrams represent the mean ± SEM of three independent experiments; \*\*P \< 0.01; \*\*\*P \< 0.001. \*\*\*\*P \< 0.0001. P‐values were calculated by unpaired two‐tailed Student\'s t‐test comparing each of the siRNAs with the negative control.

**Figure S6.** Lipid droplets confer survival advantage under starvation.

\(a\) Cell number after starvation for the indicated time period. In the feeding phase cells were incubated with OA to allow formation of TAG stores, or with solvent only. In the starvation phase cells were transferred to glucose‐free and serum‐free medium and cell number was monitored for 10 days. (b) Mitochondrial integrity in cells under starvation that have been previously fed with/without OA, determined by quantification of TMRE fluorescence, normalized to cell number. The bar diagrams represent the mean ± SEM of three independent experiments. \*\*\*P \< 0.001, unpaired two‐tailed Student\'s t‐test.

**Figure S7**: Silencing of LIPG in MDA‐MB‐468 and MCF‐7 breast cancer cells. (a) qPCR analysis showing LIPG mRNA levels in MDA‐MB‐468 cells after transfection with scrambled si‐RNA as a negative control (si‐neg) and two different si‐RNA oligos targeting LIPG (si‐LIPG‐A and si‐LIPG‐B), compared to FM (full media, non‐transfected control) and Lipo (Lipofectamine only, mock‐transfected). (b) Representative Western blot showing LIPG protein levels in the heparin‐treated cell culture supernatants (extracellular fraction), as well as in the cell lysates (intracellular fraction). For the latter, Calnexin was used as a loading control. (c) qPCR analysis showing LIPG mRNA levels in MCF‐7 cells transfected as in (a). d) Quantification of triacylglycerides (TAG) in MCF‐7 cells transfected as in (c) and cultivated for further four days. The TAG content of FM cells was taken as a reference (100%). Bar diagrams represent the mean ± SEM of three independent experiments; \*P \< 0.05; \*\*P \< 0.01; \*\*\*\*P \< 0.0001 for comparison of each of the siRNAs with the negative control (scramble, si‐neg). ^\#\#\#^P \< 0.001 for comparison of the si‐neg with the FM. P‐values were calculated by unpaired two‐tailed Student\'s t‐test.

**Figure S8**: *LIPG* is not upregulated by hypoxia. (a) qPCR analysis showing *LIPG*, *TXNRD1*, *PLIN2* and *VEGF* mRNA levels in MCF‐7 cells cultivated during the indicated time periods in hypoxic or normoxic conditions. Bar diagrams represent the mean ± SEM of three (24 h) or two (48 h and 72 h) independent experiments. \*P \< 0.05, \*\*P \< 0.01; \*\*\*\*P \< 0.0001 for comparisons with the time point 0 h. \#P \< 0.05, \#\#P \< 0.01; \#\#\#P \< 0.001; \#\#\#\#P \< 0.0001 for comparisons with normoxia conditions at a given time point. P‐values were calculated by unpaired two‐tailed Student\'s t‐test.

**Figure S9.** Treatment of MCF‐7 cells with H~2~O~2~ and rotenone upregulates *LIPG* mRNA expression. MCF‐7 cells were incubated with different concentrations of H2O2 (a) or rotenone (b) for 24 h and qPCR analysis was performed to determine mRNA gene expression of LIPG, TXNRD1 and PLIN2. Expression in untreated MCF‐7 cells was taken as the reference. UBC (ubiquitin C protein) was used as the endogenous control. The bars represent the mean ± SEM (n = 3) for H2O2 treatments and (n = 2) for rotenone treatments. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001. P‐value was calculated by unpaired, two‐tailed Student\'s t test.

**Figure S10.** Cell‐permeable reduced glutathione ethyl ester (GSH) partially abrogates CoCl~2~‐triggered response. MCF‐7 cells were incubated with 0.5 mM CoCl~2~ in the presence or absence of 50 or 500 μM GSH for 24 h and expression of *LIPG*, *PLIN2* and *TXNRD1* was analysed by qPCR. Untreated MCF‐7 cells were taken as a reference. As an endogenous control, UBC (ubiquitin C protein) was used. The bars represent the mean ± SEM (n = 2).

**Figure S11.** ROS scavengers do not prevent ROS accumulation in MCF‐7/NeuT cells.

MCF‐7/NeuT cells were incubated with dox in the presence or absence of different ROS scavengers for 6 days and expression of *LIPG*, *PLIN2* and *TXNRD1* was analysed by qPCR. (a) NAC was applied at a concentration of 1 and 10 mM; (b) MnTMPyp (TMP) was applied at a concentration of 5 and 100 μM; (c) DPI was applied at a concentration of 1 μM; and (d) lapatinib was applied at a concentration of 1 μM. Untreated MCF‐7/NeuT (−dox) cells were taken as a reference. As an endogenous control, UBC (ubiquitin C protein) was used. The bars represent the mean ± SEM (n = 2).

**Figure S12**. *LIPG* mRNA expression distribution and association with metastasis free survival (MFS) in breast cancer cohorts. Box plots and histograms showing *LIPG* mRNA distribution and Kaplan Meier plots showing association of *LIPG* mRNA expression with MFS. In the box plot and histograms the dashed line and the continuous line indicate the 95th percentile and the 98th cut‐off for LIPG respectively. In the Kaplan Meier plots *LIPG‐high* is log2 ≥ 95th percentile (left plot) and log2 ≥ 98th percentile (right plot) in each analysed cohort. The analysis was done in datasets that contained more than 50 patients and for which MFS information was available: (a) The node‐negative, adjuvantly untreated cohorts: GSE11121, GSE2034, GSE5327, and Transbig, separately and combined; (b) the tamoxifen‐treated cohorts: GSE12093, GSE17705, GSE26971, GSE6532A, GSE6532(Plus2), GSE19615(Plus2); (c) other cohorts with unknown or adjuvant treatment other than only tamoxifen: GSE2603, GSE3494, GSE45255, GSE9195(Plus2). p: P‐value of the log‐rank test; p\*: P‐value of the permutation test (when the *LIPG‐high* group contained less than 5 patients). Note that the Kaplan Meier plots and P‐values for GSE11121 and the combined cohort of node‐negative untreated patients are different than in Figure [5](#ijc32138-fig-0005){ref-type="fig"} because the plotted MFS time is 20--25 years.

**Figure S13.** *LIPG* expression and association with metastasis‐free survival (MFS) in the Cancer Genome Atlas (TCGA) breast cancer (BRCA) dataset. RNA‐sequencing data from the TCGA BRCA dataset accessed from the GDC data portal (<https://portal.gdc.cancer.gov>/) as described in (Uhlén *et al*., 2017). (a) Distribution of *LIPG* mRNA expression levels in breast tumours (n = 1,125) and matched normal breast tissue (n = 97). A pattern similar to that in the Affymetrix cohorts, with a small subset of tumours displaying high expression of LIPG, was observed. (b) Kaplan--Meier plot using the same cut‐off for high and low *LIPG* expression (98%) as in the analysis of the Affymetrix breast cancer cohorts. No significant association with shorter MFS was observed for the high *LIPG‐*expressing tumours (P = 0.245; log‐rank test), and the same was observed when applying cut‐offs at 95, and 90% to define high and low *LIPG* expression.

**Figure S14.** Association of *PLIN2* with metastasis‐free survival and independent prognostic value of LIPG. (a) Histogram of *PLIN2* expression in the combined cohort (the dashed line indicates the median) and Kaplan--Meier plot illustrating the association of *PLIN2* (log2 \> median) with shorter metastasis free survival (MFS) in the combined cohort (n = 824). p: p value from the log‐rank test. (b) Likelihood ratio (LR) plot of the combined node‐negative, adjuvantly untreated dataset (n = 824) considering *LIPG* and *PLIN2* (left panel) and *LIPG* and *TXNRD1* mRNA expression (right panel). *LIPG* was dichotomized according to the 98th percentile and *PLIN2* and *TXNRD1* were dichotomized according to the median.
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**Table S1** Clinicopathological characteristics of tumours in the Mainz TMA.

**Table S2:** Clinicopathological characteristics and literature references for the analysed cohorts

**Table S3 Lipases in oncogene‐induced senescence in MCF‐7/NeuT cells.** Summary of Affymetrix gene array analysis showing transcriptional changes of genes coding for lipases in MCF‐7/NeuT cells exposed to doxycline for different time periods to overexpress the NeuT oncogene. Gene Array expression data are shown as fold changes compared to control (gene expression of 1.0 in MCF‐7/NeuT cells not exposed to doxycycline). Values are the average of three independent experiments. Values marked with asterics represent significant changes (FDR adj. P \< 0.05).

**Table S4 Univariate and multivariate Cox analysis showing association of *LIPG* mRNA expression (Affymetrix probe set 219181_at) with metastasis free survival (MFS)** in four cohorts of node‐negative, adjuvantly untreated breast cancer patients: GSE11121 (n = 200), GSE2034 (n = 286), Transbig (GSE6532 and GSE7390, n = 280) and GSE5327 (n = 58). HR: Hazard ratio; P: P‐value (unadjusted), CI: Confidence interval.

**Table S5 Association of LIPG protein expression with clinicopathological parameters.** Expression of LIPG was determined by immunohistochemistry (IHC) in the tumour tissue microarray (TMA) of the Mainz (GSE11121) cohort. The P‐value was calculated by the two‐sided Fisher test.

**Table S6 Association of *LIPG* mRNA with clinicopathological parameters.** In a combined cohort of node‐negative untreated breast cancer patients (n = 824) consisting of the GSE11121 (n = 200), GSE2034 (n = 286), Transbig (composed of GSE6532 and GSE7390, n = 280) and GSE5327 (n = 58) cohorts, high *LIPG* expression (*LIPG* ≥ 98th percentile) was associated with grade 3 and ER‐negative status. Information on ER and HER2 status is available for all cohorts. Information on grade, age and pT stage is missing for GSE2034 and GSE5327. P‐value was calculated with two‐sided Fisher‐test.

**Table S7: Univariate and multivariate Cox analysis showing association of *PLIN2* mRNA** (Affymetrix probe set) expression with metastasis free survival (MFS) in a combined cohort of node‐negative, adjuvantly untreated breast cancer patients (n = 824) consisting of the GSE11121 (n = 200), GSE2034 (n = 286), Transbig (GSE6532 and GSE7390, n = 280) and GSE5327 (n = 58) cohorts. HR: Hazard ratio; P: P‐value (unadjusted), CI: Confidence interval.

**Table S8**: **Univariate and multivariate Cox analysis showing association of *TXNRD1* mRNA expression** with metastasis free survival (MFS) in a combined cohort of node‐negative, adjuvantly untreated breast cancer patients (n = 824) consisting of the GSE11121 (n = 200), GSE2034 (n = 286), Transbig (GSE6532 and GSE7390, n = 280) and GSE5327 (n = 58) cohorts. HR: Hazard ratio; P: P‐value (unadjusted), CI: Confidence interval.
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